Cancer News and Research

Latest Cancer News and Research

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Inflammatory myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally aggressive behavior but malignant change is rare. Such a rare tumor occurring in a 14-year-old patient with clinical presentations of abdominal pain and body weight loss was seldom described before.

18 Jun 2010

Blueberry consumption is beneficial for hepatic diseases: Study

Conventional drugs used in the treatment of liver diseases inevitably have side effects. An increasing number of natural substances have been studied to explore if they have protective effects on the liver. Blueberries have unique effects on human retinal, brain and tumor cells, but reports about the effects of blueberries on liver diseases are lacking.

18 Jun 2010

One-step surgery positively impacts patient's quality of life: Study

Restoring people's health and returning them to their daily lives as soon as possible is the goal following any surgery. When a person's ability to eat and speak is affected, as with cancer in the mouth, surgery is particularly disruptive, creating a greater challenge. A one-step surgery can remove cancerous tissue and reconstruct bone and teeth functionality immediately, positively impacting the patient's quality of life.

18 Jun 2010

Review of possible uses, limits of WB-MRI procedure

Thanks to technical progress, there are now new areas in which whole body magnetic resonance imaging can be used. In the current edition of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[22]: 383-9), Gerwin Schmidt and his coauthors present a review of possible uses, together with the limits of this radiation-free diagnostic procedure.

18 Jun 2010

Protect Your Lungs, LUNGevity Foundation announce merger

To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.

18 Jun 2010

ASH announces recipients of 2010 ASH Research Training Award for Fellows

The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.

18 Jun 2010

Researchers study risks and consequences of cigarette smoking in people living in multiple-unit housing

In an effort to protect children from harmful tobacco smoke exposure, health and medical professionals are pushing for a ban on smoking in public housing in a report appearing in this week's New England Journal of Medicine.

18 Jun 2010

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

An ubiquitin-specific peptidase that potentially promote cancer cell necrosis

"ubiquitin-specific peptidase 21 (USP21) has been identified as another essential player in regulation of tumor necrosis factor alpha (TNF-alpha)-induced nuclear factor kappaB (NF-kappaB) activation by working on receptor-interacting protein 1(RIP1)."

18 Jun 2010

IMGM acquires 3,100,000 Class B Preferred Shares of Positron

The Shareholders of Imagin Molecular Corporation ("IMGM") have approved, through a consent of over 51% of shareholder vote, certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a 1 for 100 basis into Positron common shares.

18 Jun 2010

Baylor University researchers awarded grant to research and test new compounds for cancer

The National Institutes of Health has awarded two Baylor University researchers a $1.46 million grant to research and test new compounds that could help fight cancerous tumors.

18 Jun 2010

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

Diarrhea represents a major condition responsible for pediatric mortality worldwide. The onset of neonatal diarrhea may rapidly lead to life threatening dehydration and malnutrition. Clinical and epidemiologic studies defining severity and etiology are needed in order to improve diagnostic and therapeutic approaches for the management of neonatal diarrhea.

18 Jun 2010

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

18 Jun 2010

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.

18 Jun 2010

Huntington online bill payment created to support Pelotonia bike tour for cancer research

In another bankwide effort to support the Pelotonia bike tour for cancer research, Huntington has created a way for consumers to donate to the cure for cancer through Huntington online bill payment.

18 Jun 2010

FDA approves new indication for Tasigna in treatment of rare blood cancer

The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

18 Jun 2010

Phylogeny, Neoprobe announce collaboration to develop head and neck cancer detection technology

Phylogeny, the in situ company, and Neoprobe, a diversified developer of innovative biomedical surgical oncology products, announce their collaboration to develop head and neck cancer detection technology.

18 Jun 2010

Research shows JIA patients have increased risk of cancer

Biologics-na-ve Juvenile Idiopathic Arthritis patients may have an increased risk of cancer compared with the general Swedish population, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Results of an additional study, which researched a small cohort of patients showed an increased frequency of cancer in those receiving the biologic etanercept, however, results were deemed not statistically significant by researchers.

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Blueberry consumption is beneficial for hepatic diseases: Study

One-step surgery positively impacts patient's quality of life: Study

Review of possible uses, limits of WB-MRI procedure

Protect Your Lungs, LUNGevity Foundation announce merger

ASH announces recipients of 2010 ASH Research Training Award for Fellows

Researchers study risks and consequences of cigarette smoking in people living in multiple-unit housing

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

An ubiquitin-specific peptidase that potentially promote cancer cell necrosis

IMGM acquires 3,100,000 Class B Preferred Shares of Positron

Baylor University researchers awarded grant to research and test new compounds for cancer

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Huntington online bill payment created to support Pelotonia bike tour for cancer research

FDA approves new indication for Tasigna in treatment of rare blood cancer

Phylogeny, Neoprobe announce collaboration to develop head and neck cancer detection technology

Research shows JIA patients have increased risk of cancer

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in